Diabetic retinal disease is envisioned to become the plague of the coming decades with a
steep increase of worldwide diabetes incidence followed by a substantial rise in retinal …

Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes
mellitus, representing a major cause of visual impairment in developed countries …

Aims To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without
laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients …

Introduction Diabetic retinopathy (DR) is one of the most frequent microvascular
complications of diabetes that can lead to blindness. Laser treatment has been the gold …

Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite
that DME represents a sight‐threatening condition, it is also among the most accessible to …

Objectives of the Study. Summary of observational studies concerning the pharmacological
management of diabetic macular edema (DME). Methods. A literature review was conducted …

Purpose To determine visual acuity (VA) and spectral-domain optical coherence
tomography (OCT) outcomes with intravitreal ranibizumab for diabetic macular edema …

Aim Evaluate long-term real-world treatment patterns and associated effectiveness and
safety outcomes in patients with diabetic macular edema (DME) treated≥ 36 months with …

Purpose To report the long-term outcomes of intravitreal anti–vascular endothelial growth
factor (VEGF) treatment for diabetic macular edema (DME) in a real-world clinical setting …

Aims To describe baseline characteristics and visual outcome for eyes treated with
ranibizumab for diabetic macular oedema (DMO) from a multicentre database. Methods …